Your new experience awaits. Try the new design now and help us make it even better

CLINICAL TRIAL article

Front. Oncol., 15 February 2021

Sec. Women's Cancer

Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.565384

This article is part of the Research TopicChemoresistance and Metastasis in Breast Cancer: Molecular Mechanisms and Novel Clinical StrategiesView all 24 articles

RETRACTED: A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer

Retracted

A retraction of this article was approved in:

  1. Retraction: A phase II, single-arm study of apatinib and oral etoposide in heavily pre-treated metastatic breast cancer

    1. Read retraction
Nanlin HuNanlin Hu1Anjie Zhu,Anjie Zhu1,2Yiran SiYiran Si1Jian YueJian Yue3Xue WangXue Wang3Jiayu WangJiayu Wang1Fei MaFei Ma1Binghe XuBinghe Xu1Peng Yuan*Peng Yuan3*
  • 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  • 2Department of Breast Oncology, Peking University Cancer Hospital/Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, China
  • 3Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

This article has been retracted. Please follow the link to the full retraction notice for details.

Citation: Hu N, Zhu A, Si Y, Yue J, Wang X, Wang J, Ma F, Xu B and Yuan P (2021) A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer. Front. Oncol. 10:565384. doi: 10.3389/fonc.2020.565384

Received: 19 October 2020; Accepted: 14 December 2020;
Published: 15 February 2021; Retracted: 10 February 2026.

Edited by:

Hirokazu Tanino, Kobe University, Japan

Reviewed by:

Caigang Liu, ShengJing Hospital of China Medical University, China
Dong-Xu Liu, Auckland University of Technology, New Zealand

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.